Theravance Biopharma (TBPH) Misses Q3 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
November 13, 2024 9:39 AM ESTLeerink Partners analyst David Risinger reiterated a Market Perform rating and $10.00 price target on Theravance Biopharma (NASDAQ: TBPH).
The analyst comments "TBPH reported strong 3Q24 results, including total revenue 12% above consensus and operating income 13% above, but EPS 5% below largely due a non-cash impairment... More
